Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMX101 (Imunexus)
- Development stage
- Preclinical
- Lead developer
- Imunexus
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMX101 is a preclinical bispecific antibody being developed by Imunexus Therapeutics for the treatment of small cell lung cancer (SCLC). The drug is engineered using the company's proprietary imunexin™ platform, which involves fusing an immune-activating protein (an 'imunexin') to an existing SCLC-specific monoclonal antibody. This design aims to convert a standard antibody into a multispecific therapeutic that can simultaneously bind to tumor cells and trigger a localized immune response. As of early 2024, the specific molecular targets for the SCLC-binding arm and the immune-activating component remain undisclosed.
02
Targets
CD3 (T-cell surface glycoprotein CD3)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on IMX101 (Imunexus).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMX101 (Imunexus).